Is Emergent BioSolutions Inc. (EBS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 131.4% / 30% | 47.2% / 30% | 19.3% / 30% | 4.23% / 5% | ✗ NOT HALAL |
| DJIM | 131.4% / 33% | 47.2% / 33% | 19.3% / 33% | 4.23% / 5% | ✗ NOT HALAL |
| MSCI | 43.4% / 33% | 15.6% / 33% | 6.4% / 33% | 4.23% / 5% | ✗ NOT HALAL |
| S&P | 131.4% / 33% | 47.2% / 33% | 19.3% / 33% | 4.23% / 5% | ✗ NOT HALAL |
| FTSE | 43.4% / 33% | 15.6% / 33% | 6.4% / 50% | 4.23% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 49.4% | |
| Operating Margin | -15.2% | |
| Net Margin | 7.1% | |
| Return on Equity (ROE) | 10.5% | |
| Return on Assets (ROA) | 5.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $171M |
| Free Cash Flow | $157M |
| Total Debt | $572M |
| Debt-to-Equity | 111.7 |
| Current Ratio | 5.0 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $8.08 |
| 50-Day MA | $9.99 |
| 200-Day MA | $9.42 |
| Avg Volume | 944K |
| Beta | 2.4 |
|
52-Week Range
$4.02
| |
About Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Emergent BioSolutions Inc. (EBS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Emergent BioSolutions Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Emergent BioSolutions Inc.'s debt ratio?
Emergent BioSolutions Inc.'s debt ratio is 131.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 43.4%.
What are Emergent BioSolutions Inc.'s key financial metrics?
Emergent BioSolutions Inc. has a market capitalization of $411M, trailing P/E ratio of 8.5, and revenue of $705M. The company maintains a gross margin of 49.4% and a net margin of 7.1%. Return on equity stands at 10.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.